Start Date
January 31, 2020
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2021
Alirocumab
PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
Atorvastatin 80mg
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
Ezetimibe 10mg
Cholesterol absorption inhibitor
Royal Devon & Exeter Hospital, Exeter
The Royal Bournemouth General Hospital, Bournemouth
East Sussex Healthcare NHS Trust, Saint Leonards-on-Sea
Basildon Hospital, Basildon
St Mary's Hospital, London
Queen Alexandra Hospital, Portsmouth
Southampton General Hospital, Southampton
Northwick Park Hospital, Harrow
Hull Royal Infirmary, Hull
Queens Medical Centre, Nottingham
St Peters Hospital, Chertsey
East Surrey Hospital, Redhill
Freeman Hospital, Newcastle upon Tyne
Queen Elizabeth Medical Centre, Birmingham
City Hospital, Birmingham
Worchestershire Royal Hospital, Worcester
Northern General Hospital, Sheffield
Collaborators (1)
Regeneron Pharmaceuticals
INDUSTRY
Baim Institute for Clinical Research
OTHER
Imperial College London
OTHER